A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
FILMART Online attracts 7,000 international buyers
Multifunctional online platform runs until late September Organised by the Hong Kong Trade Development Council (HKTDC), the Hong Kong International Film & TV Market (FILMART Online) concluded successfully on 29…
Singapore’s Elite Partners Acquires Warehouse in Poland for over EUR30 Million (S$48.6 Million) from Subsidiary of Sovereign Fund GIC
Elite Partners Capital (“Elite Partners” or “Elite”) announced today it has acquired a warehouse in Mszczonow, Poland for more than EUR30 million (S$48.6 million) from a subsidiary of Singapore’s sovereign…
Hepalink Announces 2020 Interim Results
Outstanding Performance in 1H2020 Revenues: +24% YoY;Profit Attributable to Equity Holders of the Company (Non-IFRS1): +669% YoY Shenzhen Hepalink Pharmaceutical Co., Ltd. (Stock Code: 9989.HK; “Hepalink” or the “Group”) today…
AIM ImmunoTech Inc.使用新的體外模型將SARS-CoV-2傳染性病毒產量降低了90％；支持進一步測試Ampligen作為預防COVID-19的鼻內預防劑
AIM ImmunoTech Inc.(NYSE – America交易代碼：AIM)欣然宣布，其已經在猶他州立大學抗病毒研究所確定了一種有效的體外模型，用於測試dsRNA TLR3激動劑Ampligen，該結果表明Ampligen能夠在臨床上可達到的鼻內Ampligen劑量水平下，將SARS-CoV-2感染性病毒的產量降低90％。這一結果支持了AIM制定使用Ampligen預防COVID-19的鼻內預防方法的目標。 AIM首席執行官Thomas K. Equels表示：“我們對這些結果感到滿意，因為它們確立了Ampligen對SARS-CoV-2的生物活性，並支持我們決定在人體內測試Ampligen作為針對COVID-19的鼻內預防和早發療法。” 正常情況下，人源的氣管/支氣管上皮細胞的3D粘膜纖毛組織培養足以模擬一些關鍵的先天免疫反應，現以證明Ampligen對SARS-CoV-2(引起COVID-19的病毒)具有預防作用。在該組織培養模型中觀察到的Ampligen的90％有效濃度(EC90)在臨床上可在人類受試者中實現，以推測可減少SARS-CoV-2。當前，缺少適當的動物模型，因此該公司在正常的人源氣管/支氣管上皮細胞的3-D體外模型中使用了SARS-CoV-2的USA-WA1 / 2020株。結果表明，在臨床上可達到的鼻內Ampligen劑量水平下，Ampligen能夠將SARS-CoV-2感染性病毒產量降低90％。這一結果支持了AIM制定使用Ampligen預防COVID-19的鼻內預防方法的目標。 人們認為Ampligen是人類先天免疫力的強大正調節劑，因此，在動物和人類實驗中，將利用活的體內先天免疫系統獲得最佳的功效度量。 在簡要回顧AIM在SARS樣疾病中的實驗歷史時，Ampligen在先前的SARS-CoV-1病毒動物實驗中顯示出明顯的活性。與SARS-CoV-1病毒小鼠模型相比，Ampligen在鹽水對照組中顯示出100％的保護性生存獲益，而死亡率則為100％。 Ampligen還可以將SARS-CoV-1肺滴度降低至檢測水平以下(Day 2009 https://tinyurl.com/y4sdb8yf 和Barnard 2006 https://tinyurl.com/y68mav9q)。但是，由於尚未設計出具有類似的設計用於復制人類對SARS-CoV-2的人類反應的小鼠的動物模型，因此AIM尋求了體外實驗模型。但是，如前所述，用於病毒實驗的典型細胞系，即克隆的AGM細胞，已經喪失了表達Ampligen生物力學的遺傳能力。這種一般效果是在2006年Barnard等人的表1中首次觀察到的。出版於《抗病毒化學和化學療法》 2006，17：275。 https://tinyurl.com/y68mav9q 另請參閱(https://tinyurl.com/y3k2qs5s) 2006年，Barnard等人在體外模型中認識到這一缺陷。然後使用體內小鼠模型，Ampligen表現出高抗病毒活性，並將SARS-CoV-1的肺滴度降低至檢測水平以下。然後，在2009年的追踪動物實驗中，Ampligen證明了100％的保護性存活，而囓齒類動物的對照組則只有100％的死亡率。 出於這些原因，在等待將來獲得體內動物實驗數據和人類臨床數據的同時，AIM則採用了這種更相關的體外模型，以使用正常，人為或由以下因素組成的模型來證明Ampligen對引起COVID -19的病毒具有積極的生物活性：衍生的氣管/支氣管上皮細胞(TBE)，已被培養形成多層，高度分化的模型，與呼吸道的上皮組織極為相似。這些細胞仍然保留了toll樣受體以及產生和反應由Ampligen誘導的干擾素的能力。 Ampligen具有抗SARS-CoV-2的生物活性，從而證明在臨床上可達到的劑量下明顯降低了感染性病毒的體外活性，這證實了我們致力於開發Ampligen作為COVID-19的預防和早期鼻內治療的承諾。 關於AIM ImmunoTech公司 AIM…
The Second “Chun Wo Innovation Student Awards” Receive Overwhelming Response – Attracts Over 70 Student Teams
Chun Wo Development Holdings Limited (“Chun Wo”), a key member of Asia Allied Infrastructure Holdings Limited (“Asia Allied Infrastructure” or “the Group”) (stock code: 00711.HK), is pleased to announce that…
Showa Denko Obtains License to Process Industrial Waste, Aiming to Promote Plastic Chemical Recycling
TOKYO, Aug 31, 2020 – Showa Denko (SDK; TSE:4004) obtained a license to process industrial waste, and started to accept used plastics which were crushed and molded. Since 2003, SDK’s…
Nissin Foods Delivers Resilient 2020 Interim Results
Revenue surges 15.9% year-on-year to HK$1,735.4 million; Net profit up 34.3% with improved margin Nissin Foods Company Limited (the “Company”, and together with its subsidiaries, the “Group”; Stock code: 1475)…
Tianneng Power’s 2020 Interim Results Scaled the Heights Again
Profit Attributable to the Owners of the Company Increased Substantially by 40.42% to RMB837 Million Basic EPS Increased by 40.42% Tianneng Power International Limited (“Tianneng Power” or the “Company”), together…
Macau E&M Holding Announces Details of Proposed Listing on the Main Board of SEHK
Global Offering of 125,000,000 Shares through Hong Kong Public Offering and International Placing Price Ranges from HK$1.00 to HK$1.20 per Share Macau E&M Holding Limited (“Macau E&M Holding”, together with…
Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates
— Supplemental NDAs for Toripalimab filed — Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies — Dual Listing on the STAR Market Junshi Biosciences…
Pizu Group Made Capital Injection to Anhui Jinding Mining Co., Ltd.
To Extend the Industrial Chain to Non-ferrous Metals,Precious Metals Mining and Development industry Pizu Group Holdings Limited (“Pizu Group” or the “Company”, together with its subsidiaries, collectively referred as the…
Kidsland Stays Resilient during Challenging 1H 2020
Strengthens Cash Management Continues Digitalization and Strategic Upgrade Kidsland International Holdings Limited (“Kidsland” or the “Group”; stock code: 2122), the largest toy retailer and distributor in China, has taken immediate…
China Success Finance Announces 2020 Interim Results
Persistently Devises Strategies in Financial Technology Steadily Developing Traditional Businesses China Success Financial Group Holdings Limited (“China Success Finance” or the “Company”, together with its subsidiaries the “Group”, stock code:…
Rimba Raya launches Seruyan River Cleanup Movement 2020
In celebration of World River Day on September 27, Rimba Raya Conservation (Rimba Raya) has partnered with the Seruyan Regency Environmental Agency to launch the Seruyan River Cleanup Movement 2020…
Duiba Group Announces 2020 Interim Results
Continuously Making Breakthrough Expanding Customer Base Revenue from User Management SaaS Business Increased Significantly by 166% Duiba Group Limited (“Duiba Group” or the “the Group”, Stock Code: 1753.HK) is pleased…
Moonstake, RAMP DEFI and Ruby Capital Join Forces
Moonstake announced a partnership with Ruby Capital and RAMP DEFI to take the next step for DeFi integration and expansion of the DeFi ecosystem. Moonstake is an advanced technology company…
Alltronics Announces 2020 Interim Results
Revenue Grows 13.7% to HK$722.8 million Business Turnaround with Net Profit of HK$42.3 million Interim Dividend at HK1.5 Cents per Share Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833),…
Edvantage Group (0382.HK) The First Phase of Sihui Campus Has Been Handed Over and Ready for Operation in Early September
New undergraduate campus createdSchool scale and condition substantially improved Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK), the largest private higher education group in Guangdong-Hong Kong-Macau…
Sino Biopharm Announces 2020 Interim Results
Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a…
Analogue Holdings Limited Announces 2020 Interim Results
Strives for Innovative Development and Overseas Expansion for Sustainable Business Growth Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries collectively the “Group”) (stock code: 1977), a leading…